Antioxidant and Hepatoprotective Effects of Silibinin in a Rat Model of Nonalcoholic Steatohepatitis by Haddad, Yara et al.
Hindawi Publishing Corporation
Evidence-Based Complementary and Alternative Medicine
Volume 2011, Article ID 647903, 10 pages
doi:10.1093/ecam/nep164
Original Article
Antioxidant and Hepatoprotective Effectsof Silibininina Rat
Model of NonalcoholicSteatohepatitis
YaraHaddad,1,2 DianeVallerand,1,2 AntoineBrault,1,2 andPierreS. Haddad1,2
1Natural Health Products and Metabolic Diseases Laboratory, Department of Pharmacology and Montreal Diabetes Research Center,
Universit´ ed eM o n t r ´ eal, Montr´ eal, QC, Canada H3C 3J7
2Institute of Nutraceutical and Functional Foods, Laval University, 2900 Boulevard Edouard Montpetit, Qu´ ebec City,
QC, Canada H3T 1J4
Correspondence should be addressed to Pierre S. Haddad, pierre.haddad@umontreal.ca
Received 11 June 2009; Accepted 15 September 2009
Copyright © 2011 Yara Haddad et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Nonalcoholic steatohepatitis (NASH) is a progressive liver disease related to the metabolic syndrome, obesity and diabetes. The
rising prevalence of NASH and the lack of eﬃcient treatments have led to the exploration of diﬀerent therapeutic approaches. Milk
thistle(Silibummarianum)isamedicinalplantusedforitshepatoprotectivepropertiesinchronicliverdiseasesincethe4thcentury
BC.W ee xplo r edthethe rape u tice ﬀectofsilibinin,theplant’smostbiologicallyactive extract,inanexperimentalratNASHmodel.
A control group was fed a standard liquid diet for 12 weeks. The other groups were fed a high-fat liquid diet for 12 weeks without
(NASH) or with simultaneous daily supplement with silibinin–phosphatidylcholine complex (Silibinin 200mg kg−1)f o rt h el a s t5
weeks.NASHratsdevelopedallkeyhallmarksofthepathology.Treatmentwithsilibininimprovedliversteatosisandinﬂammation
anddecreasedNASH-inducedlipidperoxidation,plasmainsulinandTNF-α.SilibininalsodecreasedO2
•− releaseandreturnedthe
relative liver weight as well as GSH back to normal. Our results suggest that milk thistle’s extract, silibinin, possesses antioxidant,
hypoinsulinemic and hepatoprotective properties that act against NASH-induced liver damage. This medicinal herb thus shows
promising therapeutic potential for the treatment of NASH.
1.Introduction
In industrialized countries, a sedentary lifestyle and visceral
adiposity are the main factors underlying the development
of steatosis, a benign accumulation of hepatic lipids and part
of the nonalcoholic fatty liver disease (NAFLD) spectrum.
However, nonalcoholic steatohepatitis (NASH), which is
the most serious form of NAFLD, is more likely to evolve
toward ﬁbrosis and cirrhosis. Its prevalence has exhibited
a sharp rise reaching approximately 3% of the general
population [1]. The progression from steatosis to NASH
is a numerous-hit process that is usually achieved with
the participation of dominant phenomena such as insulin
resistance,oxidativestressandinﬂammation[2,3].Although
the exact pathogenesis of NASH is yet to be understood,
several studies have focused on strongly related markers such
as lipid peroxidation, reactive oxygen species (ROS) produc-
tion, mitochondrial dysfunction, secretion of inﬂammatory
cytokines and adipokines, inﬁltration of polymorphonuclear
leukocytes, hepatocyte ballooning, formation of Mallory
bodies and collagen deposition to conﬁrm the diagnosis of
NASH or to develop new treatment strategies [2–5]. Among
these strategies, the use of complementary and alternative
medicine approaches, such as natural antioxidants and
hepatoprotectiveplantproducts,hasbeengainingpopularity
in the last decade.
Milk thistle (Silibum marianum) is the most ancient
and extensively used medicinal plant for its beneﬁcial
eﬀects on liver and other organs [6]. It was primarily
recognized for its capacity to enhance bile ﬂow and to
remove obstructions from liver and spleen [6, 7]. Silymarin,
a ﬂavolignan extracted from the fruits and seeds of the
plant, was found eﬀective for protecting against cirrhosis,
jaundice and hepatitis [7]. Furthermore, in vitro, in vivo
and clinical studies have demonstrated the antioxidant and
hepatoprotective eﬀects of silymarin and its major active
constituent silibinin (silybin), a polyphenolic molecule, in
animal and human models of alcoholic or nonalcoholic2 Evidence-Based Complementary and Alternative Medicine
chronic liver diseases [8–14]. Silibum marianum is typi-
cally administered as an encapsulated standardized extract
(70–80% silymarin) that is poorly absorbed. However,
studies carried out in rats and humans have proven the
superior bioavailability of silibinin when complexed with
phosphatidylcholine (Siliphos, Silipide) [15–18]. Indeed,
the hepatoprotective and antiﬁbrotic eﬀects of a silibinin–
vitamin E–phospholipids complex in a rat model of chronic
liver disease were demonstrated by Di Sario and colleagues
[19]. Finally, a recent pilot study has also illustrated the
eﬀectiveness of the complex in reducing insulin resistance
and plasma markers of liver ﬁbrosis in patients with NAFLD
[20]. However, no detailed analysis of the beneﬁcial eﬀect
and mode of action of silibinin, whether alone or as a
complex, has ever been reported in the context of NASH.
Thus, the present study was conducted with the objective of
evaluating the eﬃcacy of the silibinin–phosphatidylcholine
complex in protecting the liver against diet-induced NASH
in rats.
2. Methods
2.1. Chemicals. All chemicals were purchased from Sigma
Aldrich (St-Louis, USA). Silibinin was obtained from the
commercially available silibinin–phosphatidylcholine com-
plex (Siliphos, Silipide).
2.2. Animals and Experimental Procedure. A total of 20
Sprague-Dawley male rats, each weighing about 75–100g,
were purchased from Charles River, Canada (St-Constant,
Quebec). They were acclimatized to our animal care facilities
for 5 days, during which they had free access to normal rat
chow diet and water before the beginning of experimental
protocols. Rats were then randomly allocated to three
groups. The Control group comprised of six rats that were
fed with the Lieber–DeCarli standard liquid diet for 12
weeks. The NASH group, also comprised of six rats, received
the Lieber–DeCarli high-fat liquid diet for 12 weeks. The
treatment group (Silibinin) comprised of eight rats that
were fed with the same high-fat diet for 12 weeks to which
was added the silibinin–phosphatidylcholine complex, at
a dose of 200mgkg−1 (as silibinin) daily, during the last
5 weeks. Preliminary experiments conﬁrmed that cardinal
parameters of NASH were present after 7 weeks of high-
fat diet as compared with the Control group—(histology
75% of hepatocytes at stage 2 of steatosis and level 2 of
inﬂammation versus 100% of hepatocytes at stage and level
0, resp., n = 4, chi square P < .05); (malondialdehyde, MDA,
2.02 ± 0.25 versus 0.69 ± 0.06 ηmolmg−1 of protein; lactate
dehydrogenase, LDH, 95.0 ± 11.1 versus 68.3 ± 12.1 UL−1;
ATP 3.43 ± 1.22 versus 6.37 ± 0.60μmolg−1 of protein;
liver weight, LW, 15.8 ± 0.7 versus 12.8 ± 0.6g, resp.; n
= 4, P < .05)—at the time when silibinin treatment was
initiated. Diets were acquired from Dyets Inc. (Bethlehem,
PA) and mixtures were freshly prepared daily. The respective
energetic balances of each diet are listed in Lieber et al.
[21]. Animals were fed ad libitum and kept in a room with
controlled temperature and humidity, under a 12:12 h light–
dark cycle. They were monitored weekly for weight and food
consumption. All experimental protocols were approved
by the University’s Ethics Committee and accomplished in
accordance to the guidelines of the Canadian Council on the
Care of Animals.
2.3. Liver Isolation. Surgical procedure was performed after
overnight fasting, as described by Huet et al. [22]. Rats
were anesthetized with an intraperitoneal injection of
sodium pentobarbital (50mgkg−1 body weight, BW). Rats
underwent laparotomy and the portal vein was cannulated.
Blood was collected via the inferior vena cava and stored
as plasma and serum. Glycemia was directly evaluated
using a commercial glucometer (One Touch Ultra, LifeScan,
Johnson & Johnson, Milpitas, CA). Livers were ﬂushed
for 3min with Krebs–Henseleit buﬀer (NaCl 145mM, KCl
4.8mM, MgSO4 1.2mM, NaHCO3 25mM, CaCl2 2.1mM,
pH 7.4, 22◦C) then removed and weighed. Liver dissection
was subsequently performed. Sections from the median lobe
were placed in a 10% formalin solution for histopathological
analysis and other samples were immediately frozen in liquid
nitrogen and stored at –80◦C until use.
2.4. Histology. Hematoxylin phloxine saﬀron (HPS) staining
was performed on histological sections by the Department
of Histology, St-Justine’s Children Hospital (Montreal, Qc,
Canada). Scoring for steatosis was based on the percentage
of hepatocytes containing macrovesicular fat in each section
(grade 0 absent; grade 1 < 33%; grade 2 33–66%; grade 3
>66%), according to published criteria [23] .T h ed e g r e eo f
inﬂammation was based on the number of immune cells
encountered in 10 randomly selected areas (at ×400) within
each section using the following scale (0 normal; 1 mild;
2 moderate; 3 severe) [23]. Mallory bodies and collagen
deposition were evaluated as present or absent. Photos were
taken using Axio-imager electronic microscope and Axio-
vision 4.2 software (z1 Zeiss, Jena, Germany).
2.5. Blood Parameters. Plasma lipids, namely triglycerides
(TG), total cholesterol (TC), low-density lipoprotein (LDL),
high-density lipoprotein (HDL) as well as transaminases
(alanine aminotransferase, ALT, and aspartate aminotrans-
ferase, AST) and LDH were measured by the Department
of Biochemistry, St-Justine’s Children Hospital (Montreal,
Qc, Canada). Plasma tumor necrosis factor-α (TNF-α)
was assessed using Quantikine Rat TNF-α Immunoassay
Kit (R&D Systems, MN, USA). Serum adiponectin was
measured with a Rat Adiponectin ELISA Kit (AdipoGen,
Seoul, Korea). Plasma insulin was evaluated using a rat
insulin radioimmunoassay (RIA) kit (Linco Research, St.
Charles, MO). The Homeostasis Model Assessment of
Insulin Resistance (HOMA-IR) index was calculated using
circulating insulin and glucose values with the following
formula: (Fasting insulin (mUL−1) × fasting blood glucose
(mmolL−1])/22.5 [24].
2.6. Isolation of Mitochondria. Fresh liver (1g) was used
for the isolation of mitochondria, as described by John-
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was used to homogenize tissue in the isolation medium
containing sucrose (250mM), Tris–base (10mM), Ethylene
glycol tetraacetic acid (EGTA) (1mM), pH 7.2 at 4◦C. The
homogenate was then centrifuged at 600g for 10min at
4◦C, in order to remove cellular fragments. The supernatant
was collected and centrifuged at 15 000g for 5min at 4◦C.
The resulting pellet was subsequently washed gently with
the same medium, centrifuged and washed another time
with the isolation medium without EGTA and centrifuged
one last time. The ﬁnal pellet, which contained the viable
mitochondria, was suspended in this last medium and stored
on ice. Protein content was determined following the Lowry
method [26].
2.7. Assessment of Oxidative Stress Parameters. The thiobar-
bituric acid (TBA) method was used to evaluate liver lipid
peroxidation by measuring MDA levels, based on Ligeret
et al. [27]. Brieﬂy, fresh liver (0.5g) was homogenized on
ice in a sucrose buﬀer (4.5mL, 250mM) using a Teﬂon
potter homogenizer and a polytron. The homogenate was
centrifuged at 2000g for 30 min at 4◦C. The protein content
of the supernatant was determined using the Bradford
method. The supernatant (200μL) was added to a vial
containing an 8.1% (w/v) sodium dodecyl sulfate solution
(200μL), a 20% (v/v) acetic acid solution (pH 3.5) (1.5mL),
a 0.8% (w/v) TBA solution (1.5mL) and distilled water
(600μL). Vials were heated at 95◦C for 45min and cooled
on ice for 2min. Butanol (4mL) was added and all vials
were mixed for 15min and then centrifuged at 1000g for
10min. Finally, 200μL of supernatants were transferred into
a 96-well plate and Thiobarbituric Acid Reactive Substances
(TBARS) were estimated by measuring ﬂuorescence (λex =
530nm; λem = 590nm) using a multilabel counter model
Wallac Victor2 (Perkin Elmer, Woodbridge, ON). The data
were compared with a standard curve of MDA (0–84μM)
and results were expressed as nmol MDAmg−1 of protein.
The superoxide anion (O2
•−) in liver tissue was deter-
mined using the Lucigenin-ampliﬁed chemiluminescence
procedure, as described by Oliveira and colleagues [28]. In
brief, a frozen liver fragment was incubated for 15 min in an
oxygenated(95%O2 and5%CO2)Krebs-HEPESbuﬀercon-
taining NaCl (118.3mM), KCl (4.69mM), CaCl2 (1.87mM),
MgSO4 (1.2mM), KH2PO4 (1.03mM), NaHCO3 (25mM),
glucose (11.1mM) and Na-HEPES (20mM), pH 7.4, at
37◦C. The fragment was transferred into a scintillation vial
containing 2mL of this buﬀer, supplemented with lucigenin
(250mM). The scintillation counter (Wallac 1409 Model,
Perkin Elmer Life Science, St-Laurent, QC) was adjusted
for single-photon emission recording mode. The counts
appraisal was performed during a 15-min period. Data were
obtained from the area under the counts versus time curve
and expressed as a function of the dry tissue’s weight (mg).
To assess reduced glutathione (GSH), 0.5g of fresh liver
was minced on ice and then homogenized with an ice-
cold polytron, in 1mL of freshly prepared metaphosphoric
acid solution (5%). Homogenate was centrifuged at 3000g
for 10min at 4◦C. The supernatant was used for GSH
assessment using the Bioxytech GSH-400 Assay Kit (Oxis
International Inc, Portland, USA) according to the manu-
facturer’s instructions. Absorbance at 400nm was evaluated
using an Ultrospec 2100 pro spectrophotometer (Biochrom,
Cambridge, England). Data were compared with a standard
curve of reduced GSH (0–90μM).
2.8. Mitochondrial ATP. Freshly isolated mitochondria
(100μL) were added to ice-cold HClO4 (900μL, 1M) and
centrifuged at 2000g for 10min at 4◦C. The supernatant
(100μL) was neutralized with KOH (47μL, 2M) and Tris–
HCl (853μL, 100mM) [27]. Assessment of bioluminescence
was carried out using the ATP Bioluminescent Assay Kit
(SIGMA, Oakville, ON) according to the manufacturer’s
instructions with a multilabeled counter model Wallac
Victor2 (Perkin Elmer, Woodbridge, ON). The data were
then compared with a standard curve of ATP (0–80μM) and
results were expressed in μmol ATP g−1 of protein.
2.9. Western Blotting. Western blot analysis was performed
on total liver homogenate, based on Lieber et al. [21],
using a rabbit polyclonal anti-PPAR-α primary antibody
(1:400) (Santa Cruz Biotechnology Inc. Santa Cruz, CA)
and a goat polyclonal anti-rabbit secondary antibody
(1:100 000) (Jackson Immunoresearch Laboratories, Bal-
timore, PA). Liver microsomal fraction was also subjected
to western blot analysis using mouse monoclonal anti-
rat P450 CYP2E1 primary antibody (1:1000) (Oxford
Biomedical Research, Oxford, MI) and a goat anti-mouse
secondary antibody (1:4000) (Cell Signaling Technology,
Danvers, MA). Immunoreactive proteins were detected with
an enhanced chemiluminescence system according to the
manufacturer’s instructions (GE Healthcare, ECL Western
Blotting Detection Reagents, Buckinghamshire, UK). Band
quantiﬁcation was performed using ImageJ 1.37v (NIH,
USA).
2.10. Statistical Analysis. All results are expressed as means
± standard error (SE). Group means were compared by one
way ANOVA followed by Fisher’s PLSD test (and the Chi
square test for histological contingency table) using StatView
5.0.1 (SAS Institute Inc. NC). A P value < .05 was considered
statistically signiﬁcant.
3. Results
3.1. Changes in BW and LW. As shown in Table 1, there
were no signiﬁcant diﬀerences in BW or weight gain (WG)
between groups. In contrast, the high-fat diet increased the
LW in the NASH group as compared with the Control
group and this resulted in a signiﬁcant rise in liver index
(LI). Moreover, silibinin treatment during the last 5 weeks
of the high-fat diet protocol decreased the LW and the LI
signiﬁcantly when compared with the NASH group (P < .05)
and brought these parameters back to values very similar to
those observed in the Control group.
3.2. Glycemic Homeostasis. Fasting blood glucose had a
tendency to be slightly more elevated in NASH animals4 Evidence-Based Complementary and Alternative Medicine
Table 1: Eﬀect of silibinin on body and liver weight.
Parameters BW (g) WG (g) LW (g) LIa (%)
Control 559 ± 18 469 ± 6 14.2 ± 0.5 2.5 ± 0.1
NASH 526 ± 15 433 ± 17 16.7 ± 0.6∗ 3.2 ± 0.1∗
Silibinin 510 ± 12 432 ± 11 13.4 ± 0.8∗∗ 2.6 ± 0.1∗∗
ANOVA 0.065 0.085 0.0184 0.0071
Measurements were obtained from rats on the day of sacriﬁce, after
12 weeks of standard diet (control) or high-fat diet alone (NASH), or
supplemented with silibinin–phosphatidylcholine complex (Silibinin), at a
doseof200mgkg−1 assilibinin,duringthelast5weeks.Valuesareexpressed
as means ± SE of six rats for control and NASH groups and of eight rats for
Silibinin group.
aLI, LW/BW × 100.
∗P < .05 versus control group. ∗∗P < .05 versus NASH group.
than in controls or silibinin-treated congeners, albeit no
statistically signiﬁcant changes were observed (Figure 1(a)).
In contrast, 12 weeks of high-fat diet induced statistically
signiﬁcant hyperinsulinemia in NASH rats as compared
with control animals (plasma insulin values of 5.22 ± 0.98
versus 2.86 ± 0.21ngmL−1,r e s p . ;Figure 1(b), P < .05).
This situation was associated with an important increase
in insulin resistance, as demonstrated by the signiﬁcantly
higher value of HOMA-IR in NASH animals as compared
with control congeners (Figure 1(c); P < .05). Both plasma
insulin and HOMA-IR values were decreased signiﬁcantly
in Silibinin group as compared with NASH group (Figures
1(b) and 1(c); P < .05). Moreover, values in the Silibinin
group were even lower than those observed in control
animals.
3.3. Biochemical Parameters. As presented in Table 2,n o
signiﬁcant changes were observed in plasma transaminase
(ALT, AST) and TC between experimental groups. The
12-week NASH-inducing high-fat diet was associated with
a signiﬁcant increase in plasma LDH and LDL and a
signiﬁcant decrease in TG as compared with controls. HDL
also tended to be higher in NASH than in control animals.
Silibinin treatment signiﬁcantly decreased HDL and LDH
levels as compared with the NASH group. It also improved
LDL, albeit ANOVA analysis failed to reach statistical
signiﬁcance.
3.4. Histological Evaluation. Liver biopsy evaluation is
presently the gold standard test for the diagnosis of NASH.
In the Control group, liver sections exhibited normal global
histological features (CTL in Figure 2(a) and Table 3). Liver
sections from rats in the NASH group revealed that more
than one-third of hepatocytes contained macrovesicles of fat
(NASH in Figure 2(b)), which corresponded to grade 2 or 3
of steatosis (Table 3). In addition, necrotic hepatocytes, Mal-
lory bodies (NASH in Figure 2(c)) and collagen deposition
(NASH in Figure 2(d)) were exclusively found in samples
fromtheNASHgroup.A5-weektreatmentwith200mgkg−1
of silibinin promoted signiﬁcant improvement in histology
(SIL in Figure 2(e)). Indeed, >60% of rats in the Silibinin
group had less than one-third of hepatocytes containing
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Figure 1: Eﬀect of silibinin on glycemic homeostasis. Glycemia (a)
was measured in whole blood and insulin (b) was measured in
plasmaobtainedfromratsinthefastingstate,after12weeksofstan-
dard diet (control) or high-fat diet alone (NASH), or supplemented
with silibinin–phosphatidylcholine complex (Silibinin), at a dose of
200mgkg−1 as silibinin, during the last 5 weeks. HOMA-IR (c) is
indicative of the insulin resistance state for the animals. Values are
expressed as means ± SE of six rats for Control and NASH groups
and of eight rats for Silibinin group. ∗P < .05 versus Control group.
†P < .05 versus NASH group.Evidence-Based Complementary and Alternative Medicine 5
Table 2: Eﬀect of silibinin on biochemical and lipid parameters.
Parameters AST (U L−1)A L T ( U L −1) TC (mmolL−1) HDL (mmolL−1) LDL (mmolL−1) TG (mmolL−1)L D H ( U L −1)
Control 57 ± 62 8 ± 30 . 7 9 ± 0.08 0.33 ± 0.02 0.11 ± 0.04 0.65 ± 0.06 66.1 ± 6.2
NASH 64 ± 93 9 ± 60 . 8 0 ± 0.02 0.36 ± 0.04 0.23 ± 0.03∗ 0.34 ± 0.05∗ 104.1 ± 13.4∗
Silibinin 63 ± 53 1 ± 30 . 6 2 ± 0.05 0.26 ± 0.01∗∗ 0.15 ± 0.02 0.35 ± 0.03 86.3 ± 10.0∗∗
ANOVA 0.709 0.204 0.097 0.102 0.0551 0.0004 0.0442
Measurements were obtained from plasma of rats in the fasting state, after 12 weeks of standard diet (control) or high-fat diet alone (NASH), or supplemented
with silibinin–phosphatidylcholine complex (Silibinin), at a dose of 200mgkg−1 as silibinin, during the last 5 weeks. Values are expressed as means ± SE of
six rats for Control and NASH groups and of eight rats for Silibinin group. The P-values for the ANOVA Fisher’s PLSD test are given.
For pairwise comparisons, ∗P < .05 versus control group and ∗∗P < .05 versus NASH group.
Table 3:Eﬀectofsilibininonliverhistologyscoringformacrovesic-
ular steatosis and inﬂammatory cells inﬁltration.
Groups N Steatosisa Inﬂammationb
012 3 012 3
C o n t r o l 6510 0 501 0
N A S H 6001 5 003 3
Silibinin 8 3 2 1 2 2 1 4 1
Chi-square P < .05 P < .05
Histological scoring for steatosis and inﬂammation from rats fed a
standard diet for 12 weeks (control) or a high-fat diet alone (NASH), or
supplemented with silibinin-phosphatidylcholine complex (Silibinin), at a
dose of 200mgkg−1 as silibinin, during the last 5 weeks. The P values for
the Chi square test are given and diﬀerences are signiﬁcant among all groups
for both parameters.
aMacrovesicular steatosis: grade 0 absent; grade 1 < 33%; grade 2: 33–66%;
grade 3: >66%. bInﬂammation: 0 normal; 1 mild; 2 moderate; 3 severe.
macrovesicular fat (grade 0 or 1 steatosis), as compared
with rats in the NASH group (100% grade 2 or 3 steatosis).
In parallel, the liver inﬁltration of immune inﬂammatory
cells was very rarely encountered in control animals. In
contrast, 80% of NASH rats revealed inﬂammatory cell
inﬁltration ranging from moderate to severe (NASH in
Figure 2(c)). Silibinin signiﬁcantly improved this parameter
(Table 3), albeit not back to levels observed in control
animals.
3.5. Inﬂammatory Cytokines and Adipokines. Adipose tissue
and macrophages (including liver Kupﬀer cells), produce
pro-inﬂammatory cytokines such as TNF-α. During stress,
the generation of elevated amounts of TNF-α impairs insulin
signaling, leading ultimately to insulin resistance. TNF-α
was higher in the plasma of NASH rats than in that of
control rats (42.3 ± 8.8 and 15.4 ± 7.1 ρgm L −1,r e s p . ;
Figure 3(a), P < .05). Conversely, silibinin remarkably and
signiﬁcantly diminished TNF-α level (P < .05). Another
adipokine secreted by the adipose tissue is adiponectin. This
hormone is known to decrease during fatty liver disease
and the metabolic syndrome. The high-fat diet signiﬁcantly
reduced adiponectin levels in NASH rats as compared with
control animals (P < .05). The silibinin treatment caused
a considerable rise in circulating adiponectin but statistical
signiﬁcance was not achieved (Figure 3(b)).
3.6. Oxidative Stress. MDA is a lipid peroxidation product
generated during oxidative stress. As Figure 4(a) illustrates,
the NASH group exhibited a >4-fold increase in hepatic
MDA level as compared with the Control group (4.29 ±
1.05 versus 0.80 ± 0.09 ηmolmg−1 of protein, resp.; P
< .05).Lipidperoxidationwaseﬃcientlycounteractedbythe
treatmentwith200mgkg−1 ofsilibininascomparedwiththe
NASH group (P < .05).
Also during oxidative stress, the liver produces the
superoxide anion (O2
•−), an important ROS. As shown in
Figure 4(b),h e p a t i cO 2
•− level was nearly twice as high in
the NASH group as compared with the Control group (4473
± 466 and 2197 ± 190 AUCmg−1 dry tissue, resp.; P < .05).
Silibinin was able to signiﬁcantly reduce O2
•− to 2267 ± 267
AUC mg−1 dry tissue (P < .05 versusNASH animals), a value
very similar to that of the Control group.
Hepatic reduced GSH is a potent antioxidant, also
producedbytheliverasamechanismofintracellulardefense.
As illustrated by Figure 4(c), GSH level was signiﬁcantly
higher in the NASH group than in the Control group
(16.8 ± 1.2 versus 9.8 ± 0.4mmolg−1 of protein, resp.;
P < .05). The silibinin treatment signiﬁcantly diminished
hepatic glutathione to a value of 9.3 ± 0.4mmolg−1 of
protein, which is equivalent to that of the Control group.
3.7. Mitochondrial Dysfunction. The high-fat treatment
caused a signiﬁcant decrease in hepatic mitochondrial ATP
production, as observed in the NASH group compared with
the Control group (Figure 5; P < .05). This cellular energetic
imbalance was not corrected by silibinin treatment.
3.8. Expression of CYP2E1 and PPAR-α. Impaired mito-
chondrial β-oxidation as well as increased peroxisomal β-
oxidation and microsomal ω-oxidation of free fatty acids
(FFAs) in hepatocytes lead to the overproduction of ketones.
The cytochrome P450 CYP2E1 is the metabolizing enzyme
upregulated by elevated levels of ketone bodies in the liver.
As shown in Figure 6(a), the high-fat diet caused an increase
in the microsomal expression of cytochrome P450 CYP2E1
in livers of the NASH rats (84% above control, P < .05).
CYP2E1 expression was unchanged in the Silibinin group as
compared with the NASH group.
An important transcription factor responsible for the
activation of fat metabolism genes is the peroxisome
proliferator-activated receptor-α (PPAR-α). Its expression
was decreased in livers of NASH animals as compared with6 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Eﬀect of silibinin on liver histology. Representative HPS staining of rat liver sections. The Control (a-CTL; ×20) group received
12 weeks of standard liquid diet and showed normal histology. The NASH (b–d NASH; ×10, ×40 and ×20, resp.) group received a
high-fat liquid diet during 12 weeks and revealed severe steatosis, hepatocyte ballooning, important inﬂammatory cell inﬁltration such as
monocytes (M) and neutrophils (N), necrosis (Nec), Mallory bodies (Mallory) and ﬁbrosis. A 12-week high-fat liquid diet supplemented
with silibinin–phosphatidylcholine complex (e-SIL; ×20), at a dose of 200mgkg−1 as silibinin during the last 5 weeks, displayed mild
steatosis and moderate inﬂammation.
values observed in the Control group (34% of control, P
< .05), Silibinin treatment failed to return the expression of
PPAR-α t oc o n t r o ll e v e l s( Figure 6(b)).
4. Discussion
NASH is a severe subset of NAFLD that may evolve to
cirrhosis and liver failure. Its prevalence is increasing in
global populations due to the rising incidence of its closely
related conditions, namely visceral adiposity, the metabolic
syndromeanddiabetesmellitus[29].Atpresent,nopharma-
cological treatment has been convincingly eﬃcient against
NASH. In fact, slight but consistent weight loss, healthy
eating regimen and exercise together with a number of
therapeutic avenues, remain the center of all strategies to
improve or reverse the main NASH-induced injuries [30,
31]. With the rising interest in complementary and alter-
native medicine, notably in the western hemisphere, several
natural products have raised interest for their potential
beneﬁcial eﬀects in liver diseases. Among such attractive
novel therapeutic possibilities, milk thistle and its major
active compounds have caught our interest because of their
various properties known, for centuries, to be beneﬁcial
in liver disease. These properties, namely antioxidant, hep-
atoprotective and mitochondrial-protective properties, were
also demonstrated in our previous study in which silibinin
aﬀorded mitochondrial and antioxidant protection against
liver injuries induced by cold preservation/warm reperfusion
in rats [27]. Considering that all the aforementioned features
contribute to the pathogenesis of NASH, we therefore
evaluatedthe beneﬁcialeﬀectsof silibinin in an experimental
in vivo rat model of NASH.
To induce the pathology, we selected a dietary model
developed by Lieber and colleagues [21] that reproduces
the dominant clinical features of NASH in rats, following
the consumption of a high-fat liquid diet. This model
appropriately mimics the human condition given that NASH
is intimately associated with a fat-rich sedentary life-style
in obese and non-obese patients [32]. Our results clearly
demonstrate that the ingestion of the Lieber liquid high-fat
diet during 12 weeks produces all the prominent character-
istics of NASH. Furthermore, it is important to note that the
principal histological features of NASH, including steatosis,
inﬂammation and ﬁbrosis, were found in preliminary exper-
iments to be already present after 7 weeks of the Lieber diet.
Therefore, rats received the silibinin therapy during the last
5 weeks of the 12-week experiment with the objective of
treating the disease.
Treatment with 200mgkg−1 of silibinin (added to the
diet as a silibinin–phosphatidylcholine complex) during
these 5 weeks, along with the uninterrupted intake of the
high-fat diet, was very eﬃcient at reversing the progression
of NASH. Indeed, accumulation of fat in the liver was sig-
niﬁcantly reduced, as indicated by the improved histologicalEvidence-Based Complementary and Alternative Medicine 7
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Figure 3: Eﬀect of silibinin on inﬂammatory cytokines and
adipokines. TNF-α (a) and adiponectin (b) were measured using
ELISA kits in plasma and serum, respectively, and were obtained
from rats in the fasting state, after 12 weeks of standard diet (con-
trol), high-fat diet alone (NASH) or supplemented with silibinin–
phosphatidylcholine complex (Silibinin), at a dose of 200mgkg−1
as silibinin, during the last 5 weeks. Values are expressed as means
± SE of six rats for control and NASH groups and of eight rats
for Silibinin group. ∗P < .05 versus control group. †P < .05 versus
NASH group.
grade of steatosis and by the normalization of liver weight,
liver index as well as plasma lipid levels (notably LDL,
HDL and TC). Despite this, silibinin treatment failed to
restore impaired PPAR-αexpressionortoreducetheelevated
expression of CYP 2E1. A reducing eﬀe c to nC Y P2 E 1w a s
previously reported in human hepatocytes but required very
high doses of the milk thistle component [33].
On the other hand, insulin sensitivity was restored by
silibinin treatment as suggested by normalized insulinemia
and HOMA-IR, despite the continued intake of the NASH-
inducing high-fat diet. This hypoinsulinemic eﬀect was
shown in a previous clinical trial on cirrhotic diabetic
patients [12]. There was also a tendency for silibinin
to reverse the NASH-induced reduction of circulating
adiponectin,consistentwiththereversalofinsulinresistance.
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Figure 4: Eﬀect of silibinin on oxidative stress parameters. Hepatic
MDA (a), O2
•− production (b) and GSH concentration (c) were
measured in fresh or frozen liver tissue obtained from rats in the
fasting state, after 12 weeks of standard diet (control), high-fat diet
alone (NASH) or supplemented with silibinin–phosphatidylcholine
complex (Silibinin), at a dose of 200mgkg−1 as silibinin, during
the last 5 weeks. Values are expressed as means ± SE of six rats for
control and NASH groups and of eight rats for Silibinin group. ∗P
< .05 versus Control group. †P < .05 versus NASH group.8 Evidence-Based Complementary and Alternative Medicine
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Figure 5: Eﬀect of silibinin on mitochondrial ATP. ATP was
measuredinfreshlyisolatedmitochondriaobtainedfromratsinthe
fasting state, after 12 weeks of standard diet (control), high-fat diet
alone (NASH) or supplemented with silibinin–phosphatidylcholine
complex (Silibinin), at a dose of 200mgkg−1 as silibinin, during
the last 5 weeks. Values are expressed as means ± SE of six rats for
control and NASH groups and of eight rats for Silibinin group. ∗P
< .05 versus control group.
Such an insulin-sensitizing eﬀect was previously observed in
patients with chronic liver damage that were treated with a
silibinin–vitamin E–phospholipids complex[20].Partof this
eﬀect was attributed to the antioxidant properties of silibinin
[12] because of its capacity to decrease lipid peroxidation, to
reduce the release of O2
•− and to restore hepatic GSH level
[34, 35]. Indeed, the latter was evident in the present study
from the return to normal of all hepatic oxidative stress
parameters (lipid peroxidation, ROS generation, reduced
glutathione).
Likewise, the hepatoprotective eﬀect of silibinin was
conﬁrmed by the normalized level of circulating LDH and
supported by the tendency to restore the NASH-induced loss
of mitochondrial ATP. In addition, silibinin treatment sig-
niﬁcantly improved all indicators of inﬂammation that were
heightened by the induction of NASH. Indeed, the inﬁltra-
tion of immune cells into liver tissue was signiﬁcantly dimin-
ished and circulating TNF-α level was remarkably reduced.
Moreover, the livers of silibinin-treated rats were devoid of
necrosis, Mallory bodies and ﬁbrosis. In fact, silibinin was
shown to be antiﬁbrogenic in the liver by reducing activation
and proliferation of isolated and cultured stellate cells [36]
and by decreasing collagen accumulation in experimental
liver ﬁbrosis [37, 38] in rats. The hepatoprotective, antiox-
idant and antiﬁbrogenic eﬀects of silibinin observed herein
are also consistent with previous studies [34, 35, 37–41].
In summary, our understanding of the NASH pathology
based on the obtained results leans toward the popular
theory of the multiple-hit process leading to cellular and
molecular injuries. As mentioned previously, an accumula-
tion of macrovesicular fat accompanied by elevated oxidative
stress production within the hepatocytes, along with inﬂam-
mation and insulin resistance represent the key factors in the
development of a steatohepatitis, as illustrated in Figure 7.
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Figure 6:EﬀectofsilibininonCYP2E1andPPAR-α.Representative
western blots presented were performed on liver microsomal
fraction for CYP2E1 (a) or whole liver homogenates for PPAR-α (b)
to reveal their protein expression. Livers were obtained from rats in
the fasting state, after 12 weeks of standard diet (CTL), high-fat diet
alone (NASH) or supplemented with silibinin–phosphatidylcholine
complex (SIL), at a dose of 200mgkg−1 as silibinin, during the last
5weeks.Valuesareexpressedasmeans ±SEof6–8samplesforeach
group. ∗P < .05 versus control group.
On the other hand, our results also allow us to speculate
on the main points of action of silibinin being steatosis,
inﬂammation, oxidative stress and insulin resistance
(Figure 7).
Overall, our study clearly conﬁrms that silibinin, a
natural hepatoprotectant, is eﬃcient at improving injuries
caused by a chronic liver disease. It also demonstrates for
the ﬁrst time that a therapeutic treatment with silibinin,
administrated as a complex with phosphatidylcholine, is
eﬀective in reversing steatosis, inﬂammation, oxidative stress
and insulin resistance in an in vivo rat model of diet-induced
NASH. These results are very promising and, given theEvidence-Based Complementary and Alternative Medicine 9
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Figure 7: Pathogenesis of NASH and major action ﬁelds of the Silibinin treatment. Main results-deﬁned pathological pathway leading to
NASH and key action points of Silibinin in the liver to reverse the disease’s development. mito, mitochondria; HNE, trans-4-hydroxy-2-
nonenal; VLDL, very low density lipoproteins; arrow: induces; blunt arrow: inhibits; plus: increases; minus: decreases.
fact that silibinin has already been used safely in humans
suﬀering from chronic liver disease, encourage us to propose
that this novel therapeutic approach for NASH be tested in
future clinical studies.
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